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Abstract. Raf-1 kinase inhibitor protein (RKIP) is a tumor 
suppressor and metastasis inhibitor, which enhances 
drug-induced apoptosis of cancer cells. Downregulation of 
RKIP may be significant in the biology of highly aggressive 
and drug-resistant tumors, for example triple-negative breast 
cancers (TNBCs). Potential causes for the low levels of 
RKIP expressed by SUM 159 TNBC cells were investigated 
in the present study. Bisulphite modification, methylation 
specific-polymerase chain reaction (PCR) and a TransAM 
NF-κB assay were performed and the results suggested 
that various mechanisms, including methylation of the 
gene promoter, histone deacetylation and nuclear factor-κB 
(NF-κB) activation, but not targeting by microRNA-224 
(miR/miRNA-224), as determined by transfection of 
pre-miR-224 miRNA precursor or anti-miR-224 miRNA 
inhibitor, may downregulate RKIP in these cells. Furthermore, 
reverse transcription‑quantitative PCR, western blotting, 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulphophenyl)-2H-tetrazolium cell growth assay and flow 
cytometry revealed that in SUM 159 cells, the demethylating 
agent 5-aza-2'-deoxycytidine (5-AZA), the histone deacetylase 
inhibitor trichostatin A (TSA) and the NF-κB inhibitor dehy-
droxymethylepoxyquinomicin (DHMEQ) enhanced RKIP 
expression and resulted in significant cell growth inhibition 
and induction of apoptosis. 5-AZA and TSA mainly produced 
additive antitumor effects, while the combination of DHMEQ 
and TSA exhibited significant synergy in cell growth inhibi-
tion and induction of apoptosis assays. Increasing evidence 
that aberrant activation of NF-κB signaling is a frequent char-
acteristic of TNBC highlights the fact that this transcription 
factor may be a useful target for treatment of such tumors. In 
addition to DHMEQ, proteasome inhibitors may also repre-
sent valuable therapeutic resources in this context. Notably, 
proteasome inhibitors, in addition to the inhibition of NF-κB 
activation, may also restore RKIP levels by inhibiting protea-
some degradation of the ubiquitinated protein. The current 
results contribute to the understanding of the molecular 
mechanisms of RKIP downregulation in TNBC and suggest 
possible novel therapeutic approaches for the treatment of 
these types of cancer.
Introduction
A major challenge in the field of breast cancer is the iden-
tification and exploitation of useful therapeutic targets for 
the most aggressive forms. Among these, the triple-negative 
breast cancers (TNBCs), characterized by a lack of estrogen, 
progesterone and human epidermal growth factor receptor-2 
(HER2) receptors, are a highly heterogeneous group of 
tumors which account for ~15% of all breast cancers. TNBCs 
are often associated with epithelial-mesenchymal transition 
and a high propensity for early metastasis (1). To date, no 
molecularly‑targeted therapeutic agents are clinically avail-
able for TNBCs, therefore these tumors, which are frequently 
resistant to cytotoxic chemotherapy, remain challenging to 
treat. Nevertheless, progress is being made in the subtyping of 
TNBCs following the identification of molecular alterations, 
which current therapeutic efforts are focused towards (2).
With regard to the identification of molecular alterations 
in TNBCs, various studies have indicated the potential impor-
tance of the dysregulation of the Raf-1 kinase inhibitor protein 
(RKIP) signaling pathway in breast cancer metastasis and the 
biology of TNBCs (3-5). RKIP inhibits the Raf-1/mitogen-acti-
vated protein kinase kinase interaction and thus the oncogenic 
activities of the mitogen activated protein kinase pathway (6). 
RKIP also affects the activation of nuclear factor-κB (NF-κB) 
and signal transducer and activator of transcription-3 (7,8), 
antagonizing their pro-oncogenic effects. In its phosphoryl-
ated state, RKIP downregulates numerous G protein-coupled 
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receptors and may also be involved in regulation of the parti-
tioning of chromosomes and progression through mitosis (9,10). 
Overall, RKIP is a tumor and metastasis suppressor, which is 
downregulated in numerous types of cancer, including breast 
cancer, and is correlated with a more severe prognosis (11). 
Furthermore, RKIP is able to promote drug-induced apoptosis 
in cancer cells (12), underscoring the need for novel approaches 
for the rescue of RKIP expression levels in neoplastic tissues.
Unfortunately, the causes underlying RKIP downregulation 
in these tumors remain to be elucidated. In the case of breast 
cancer, the reduction in RKIP has been associated with tran-
scriptional repression by the NF-κB/Snail pathway (13,14) or the 
polycomb protein enhancer of zeste homolog 2 (15), as well as 
silencing by microRNA-224 (miR-224) (16).
The present study aimed to examine the potential relevance 
of various mechanisms underlying the low levels of RKIP 
exhibited by the SUM 159 TNBC cell line.
Materials and methods
Reagents. The demethylating agent 5-aza-2'-deoxycytidine 
(5-AZA) and the histone deacetylase (HDAC) inhibitor tricho-
statin A (TSA) were purchased from Sigma-Aldrich Srl, Milan, 
Italy. The NF-κB inhibitor dehydroxymethylepoxyquinomicin 
(DHMEQ) was provided by Professor Kazuo Umezawa 
(Department of Applied Chemistry, Faculty of Science and 
Technology, Keio University, Yokohama, Japan).
Cell cultures. The BT 549, MCF 7, MCF 7R and MDA MB 231 cell 
lines were cultured in RPMI-1640, the MDA MB 468 cell 
line was cultured in Dulbecco's modified Eagle's medium 
(DMEM), the SUM 159 and SUM 149 cell lines were cultured 
in DMEM/F-12 supplemented with insulin (5 µg/ml), and the 
MCF 10A cell line was cultured in DMEM/F-12 supplemented 
with insulin (0.01 mg/ml), epidermal growth factor (20 ng/ml) 
and hydrocortisone (500 ng/ml). All media were supplemented 
with 10% heat‑inactivated fetal calf serum, 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin (all reagents 
were from EuroClone S.p.A., Milan, Italy; GE Healthcare Life 
Sciences, Logan, UT, USA). The cells were cultured in a humidi-
fied atmosphere at 37˚C in 5% CO2. After obtaining the cells, the 
first passage carried out was assigned passage number 1. Cells 
with a narrow range of passage number (4‑6) that were routinely 
tested for Mycoplasma contamination were used for all experi-
ments. The breast carcinoma MCF-7 line was purchased from 
the American Type Culture Collection (Manassas, VA, USA) 
and its multi‑drug resistant variant MCF‑7R was established by 
treating the wild-type MCF-7 cells with gradually increasing 
concentrations of doxorubicin. Non-malignant MCF 10A breast 
epithelial cells were provided by Dr. Agata Giallongo (Institute 
of Biomedicine and Molecular Immunology, National Research 
Council, Palermo, Italy) and TNBC cell lines were provided by 
Dr. Elda Tagliabue (Molecular Targeting Unit, Department of 
Experimental Oncology and Molecular Medicine, Fondazione 
Institute of Hospitalization and Scientific Care, National Cancer 
Institute, Milan, Italy).
Cell growth assays. The cells were seeded at 2x104 cells/well 
onto 96‑well plates and incubated overnight at 37˚C. At 
time 0, the medium was replaced with fresh complete medium 
supplemented with 5‑AZA, TSA, DHMEQ or combinations 
of AZA + TSA or DHMEQ + TSA at the indicated concentra-
tions. Following 72 h of treatment, 15 µl commercial solution 
obtained from Promega Corp. (Madison, WI, USA) containing 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(
4-sulphophenyl)-2H-tetrazolium (MTS) and phenazine etho-
sulfate was added. The plates were incubated in a humidified 
atmosphere at 37˚C in 5% CO2 for 2 h, and the bioreduction of 
MTS dye was evaluated by measuring the absorbance of each 
well at 490 nm using a microplate absorbance reader (iMark 
Microplate Reader; Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). Cell growth inhibition was expressed as a percentage of 
the absorbance of the control cells. For the combinations, to 
evaluate the type of interaction between the agents, dose‑effect 
curves were analyzed according to the Chou and Talalay 
method (17) using CalcuSyn® software (version 2.1; Biosoft, 
Cambridge, UK) as a non-constant ratio combination. The 
combination index (CI) indicates a quantitative measure of 
the degree of drug interaction in terms of synergistic (CI<1), 
additive (CI=1) or antagonistic (CI>1) effects.
Evaluation of cell death by flow cytometry. SUM 159 cells 
were treated with the agents alone or in combination for 48 h. 
Subsequently, the cells were washed twice with ice‑cold 
phosphate-buffered saline (PBS; EuroClone S.p.A.) and then 
suspended at a density of 1x106 cells/ml in a hypotonic fluoro-
chrome solution containing 50 µg/ml propidium iodide in 0.1% 
sodium citrate with 0.03% (v/v) Nonidet P‑40 (Sigma-Aldrich 
Srl). Following incubation in this solution for 1 h, the samples 
were filtered through a 40-µm mesh nylon cloth, and fluores-
cence was evaluated as single-parameter frequency histograms 
using a FACSort instrument (BD Biosciences, San Jose, CA, 
USA). The data were analyzed using CellQuest™ software 
(version 3.1; BD Biosciences). Cell death was measured by 
determination of the percentage of events accumulated in the 
pre-G0-G1 position.
DNA extraction and bisulphite modification. Ten breast 
cancer samples were obtained from the Anatomic Pathology 
Unit, University Hospital ̔Paolo Giaccone̓ (Palermo, Italy) 
between 2013 and 2014. This study was approved by the 
ethics commitee of the University of Palermo (Palermo, Italy) 
and written informed consent was obtained from all patients. 
Two 8-µm sections microdissected from each of the ten 
paraffin‑embedded samples. Cell lysis and DNA extraction 
were performed on the ten samples, as well as SUM 159 cells, 
using a QIAamp DNA mini kit (Qiagen GmbH, Hilden 
Germany) according to the manufacturer's protocol. Extracted 
genomic DNA was diluted in 50 µl distilled water. Sodium 
bisulphite conversion was performed using the EpiTect Plus 
Bisulfite Conversion kit (Qiagen GmbH) using 500 ng DNA, 
according to the manufacturer's protocol.
Immunohistochemical analysis. Evaluation of the positivity 
for Ki‑67, ER and PR, HER2 and RKIP protein was performed 
by immunohistochemistry, as previously described (18,19). 
Briefly, tissue samples were fixed in 10% buffered formalin 
and paraffin‑embedded. Tissue sections (4 µm) were then 
deparaffinized and rehydrated. The sections were pretreated 
with Tris/EDTA buffer (pH 9.0; Novocastra Reagents, Milton 
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Keynes, UK) and Cell Condition Solution (Ventana Medical 
Systems, Inc., Tucson, AZ, USA) in a PT Link pre-treatment 
system (Dako UK Ltd., Ely, UK) at 98˚C for 30 min. 
Subsequently, the sections were washed in PBS at room 
temperature. The endogenous peroxidase was neutralized 
using 3% H2O2 and the membranes were blocked using 4% 
casein (Novocastra Reagents). The samples were then incu-
bated for 1 h at room temperature with the following primary 
antibodies: Polyclonal rabbit anti-human RKIP (1:100; 
cat. no 4742; Cell Signaling Technology Inc., Danvers, MA, 
USA), monoclonal rabbit anti-human estrogen receptor, (clone 
SP1; 1:100; cat. no. 790-4324; Ventana Medical Systems), 
monoclonal rabbit anti-human progesterone receptor (clone 
1E2; 1:100; cat. no. 790-2223; Ventana Medical Systems), 
rabbit anti‑human monoclonal Ki‑67 (clone 30‑9; 1:500; 
cat. no. 790‑4286; Ventana Medical Systems). Staining was 
detected using a polymer detection kit (Novocastra Reagents) 
and 3,3'‑diaminobenzidine substrate‑chromogen (Novocastra 
Reagents) and the slides were counterstained using Harris 
hematoxylin (Novocastra Reagents).
Methylation‑specific polymerase chain reaction (PCR). 
Methylation of the RKIP gene promoter was investigated 
using methylation‑specific PCR. The reaction was performed 
in a total volume of 50 µl, comprised of 6 µl bisulphite 
modified DNA, 0.2 µM each sense and anti‑sense primers 
(Invitrogen Life Technologies, Carlsbad, CA, USA), 1 µl 
dNTPs (0.2 mM each), 1,5 mM MgCl2, 1X PCR buffer 
and 1 unit Platinum Taq DNA Polymerase (Invitrogen Life 
Technologies). The cycling conditions were as follows: 
Initial denaturation at 95˚C for 10 min, followed by 40 cycles 
of denaturation at 95˚C for 1 min, annealing at 52˚C for 
1 min and extension at 72˚C for 1 min, followed by a final 
extension step at 72˚C for 10 min. To differentiate between 
the methylated DNA (204 bp PCR product) and the 
unmethylated DNA (205 bp PCR product), the following 
specific primers were used: Unmethylated RKIP promoter 
forward, 5'-TTTAGTGATATTTTTTGAGATATGA-3' and 
reverse, 3'-CACTCCCTAACCTCTAATTAACCAA-5'; 
methylated RKIP promoter forward, 5'-TTTAGCGAT 
ATTTTTTGAGATACGA‑3' and reverse, 3'‑GCTCCCTAA 
CCTCTAATTAACCG-5' (Applied Biosystems Life 
Technologies, Foster City, CA, USA). 
CpGenome universal methylated DNA (Chemicon 
International, Inc., Temecula, CA, USA) was used as a meth-
ylated positive control. Blood DNA obtained from a healthy, 
young individual was used as an unmethylated negative 
control following receipt of written informed consent.
Cell transfection with anti‑miR microRNA (miRNA) inhib‑
itor and pre‑miR miRNA precursor. SUM 159 cells were 
transfected with 30 nM pre-miR-224 miRNA precursor, 
anti‑miR‑224 miRNA inhibitor and relative random 
sequences (pre‑miR negative control) as negative controls, 
using siPORT™ Amine Transfection Agent (all these 
reagents were from Ambion Life Technologies, Carlsbad, 
CA, USA), according to the manufacturer's instructions.
Extraction of cellular RNA and reverse transcription‑quanti‑
tative PCR (RT‑qPCR). Total RNA was extracted from clinical 
samples and cell lines using TRIzol reagent (Invitrogen Life 
Technologies). For the evaluation of miR‑224 levels, mature 
miRNA was reverse transcribed using miRNA-specific 
stem‑loop pr imers (TaqMan MicroRNA Reverse 
Transcription kit; Applied Biosystems Life Technologies) 
prior to qPCR, which was conducted according to the manu-
facturer's instructions (TaqMan MicroRNA assay; Applied 
Biosystems Life Technologies) on a StepOne RealTime PCR 
System (Applied Biosystems Life Technologies). The PCR 
cycling conditions were as follows: Denaturation at 50˚C for 
2 min, annealing at 95˚C for 10 min, followed by 40 cycles 
of 95˚C for 15 sec and extension at 60˚C for 60 min. Samples 
were normalized to RNU6B small RNA.
For the evaluation of RKIP expression, RNA was reverse 
transcribed using a high capacity complementary DNA 
(cDNA) reverse transcription kit (Applied Biosystems Life 
Technologies). The resulting cDNAs were subjected to 
real‑time RT‑PCR using the TaqMan Gene Expression Master 
Mix kit (Applied Biosystems Life Technologies) in triplicates. 
The PCR cycling conditions were as follows: Denaturation 
Table I. RKIP and miR‑224 expression levels in various breast cancer cell lines.
Cell line RKIP protein levels RKIP mRNA levels miR‑224 levels
MDA 231 0.717 0.500 0.815
MDA 468 0.980 0.768 0.013
BT 549 0.686 0.136 0.101
SUM 149 1.131 0.866 3.964
SUM 159 0.559 0.402 0.923
MCF 10A 1.063 1.000 1.000
MCF 7 1.667 1.130 0.001
MCF 7R 1.069 0.390 0.000
MCF 10A cell line was used as a control reference for the evaluation of RKIP mRNA and miR‑224 expression levels by quantitative poly-
merase chain reaction. For the evaluation of RKIP protein expression, immunoblots were quantified by densitometry and Pearson's correlation 
coefficients were determined. Results were then expressed as arbitrary units (RKIP/β-actin). RKIP, Raf-1 kinase inhibitor protein; miR-224, 
microRNA-224; mRNA, messenger RNA.
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at 50˚C for 2 min, annealing at 95˚C for 10 min, followed by 
40 cycles of 95˚C for 15 sec and extension at 60˚C for 60 min. 
The running of the samples and data collection were performed 
on a StepOne AB Real Time PCR system (Applied Biosystems 
Life Technologies). β-actin was used as an internal standard. 
The specific primers used were as follows: hsa-miR-224, 
002099; RNU 6B, 001093; RKIP, Hs01110783_g1; and β-actin, 
Hs99999903_m1 (Applied Biosystems Life Technologies).
Relative expression was calculated using the comparative 
Ct method [ΔCt=Ct(target gene)-Ct(housekeeping gene)]. Where Ct was 
the fractional cycle number at which the fluorescence of each 
sample passed the fixed threshold. Fluorescence was measured 
at 515-518 nm using StepOne AB Real Time PCR System 
software (Applied Biosystems Life Technologies). The ΔΔCt 
method for relative quantification of gene expression was used 
to determine miRNA or gene expression levels. ΔΔCt was 
calculated using the formula: ΔΔCt=ΔCt(each sample)-ΔCt(reference 
sample). Fold change was calculated using the 2-ΔΔCt equation.
Table IV. Results of cell growth assays of SUM 159 cells fol-
lowing treatment with various concentrations of 5‑AZA, TSA 
or DHMEQ.
Treatment Cell growth inhibition, %
5-AZA, mM
  0.5 1.1±0.2b
  0.75 6.0±2.0b
  1.0 5.2±1.9a
  2.0 40.1±4.9b
TSA, µM
  0.5 5.8±2.9a
  0.75 19.2±3.7b
  1.0 24. 5±4.9b
  1.5 43.1±4.4b
  2.0 83.1±2.1b
DHMEQ, µg/ml
  5.0 0.0
  7.5 0.2±0.2
  10 0.3±0.5
  15 2.5±2.0
  20 2.0±0.7b
aP<0.05 and bP<0.01 vs. control. Data are expressed as the 
mean ± standard deviation of three independent experiments. 5-AZA, 
5‑aza‑2'‑deoxycytidine; TSA, trichostatin A; DHMEQ, dehydroxy-
methylepoxyquinomicin.
Table II. Characteristics of ten breast cancer samples. 
       Methylation RKIP  Lymph
       of RKIP mRNA RKIP node
Sample Histotype Grading Ki‑67 ER PR HER2 gene promoter levels protein metastasis
T1 Luminal A G1 Pos<5% + + - + 0.058 - -
T2 Luminal A G2 Pos<10% + + - + 0.279 - -
T3 Luminal A G2 Pos<10% + + - + 0.352 - +
T4 Luminal B G2 Pos<10% + + + + 0.426 ‑ ‑
T5 Luminal A G2 Pos<10% + + - + 0.355 - -
T6 TN G3 Pos<10% ‑ ‑ ‑ ‑ 1.068 + +
T7 Luminal B G3 Pos>10% + + + - 0.477 + -
T8 TN G3 Pos>10% - - - - 0.493 + -
T9 TN G3 Pos>10% ‑ ‑ ‑ ‑ 0.627 + +
T10 Basal-like G3 Pos>50% - - - - 0.494 + +
 CK 5/6+
A healthy sample was used as control reference for the analysis of RKIP mRNA expression levels by quantitative polymerase chain reaction. 
TN, triple negative; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor‑2; RKIP, Ras‑1 kinase 
inhibitor protein; mRNA, messenger RNA; Pos, positive expression; CK, cytokeratin.
Table III. RKIP mRNA and protein levels in SUM 159 cells 
following treatment with 5-AZA, TSA or a combination of the 
two for 72 h.





Untreated SUM 159 cells were used as control reference for the 
determination of RKIP mRNA expression levels by quantitative 
polymerase chain reaction. For RKIP protein, immunoblots were 
quantified by densitometry and results were expressed as arbitrary 
units (RKIP/β-actin). 5-AZA and TSA were used at concentrations of 
2 mM and 1 µM, respectively. Data are expressed as the mean ± stan-
dard deviation of three independent experiments. aP<0.05 and bP<0.01 
vs. control. RKIP, Ras‑1 kinase inhibitor protein; mRNA, messenger 
RNA; 5-AZA, 5-aza-2'-deoxycytidine; TSA, trichostatin A.
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Western blotting. Whole-cell lysates were obtained from 
breast cancer cells using radioimmunoprecipitation assay 
buffer (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and 
25 µg protein was subjected to 10% SDS-PAGE and transferred 
to Hybond-P membranes (GE Healthcare Europe GmbH, 
Freiburg, Germany). Filters were incubated with primary 
antibodies raised against β-actin (1:10,000; Sigma-Aldrich 
Srl) or RKIP (1:1,000; Cell Signaling Technology, Inc.). 
Immunoblots were quantified by densitometry and results 
were expressed as arbitrary units (RKIP/β-actin).
Cell invasion assay. Cell invasion assays were performed 
using BD BioCoat  Mat r igel  Invasion Chambers 
(BD Biosciences). SUM 159 cells were seeded at a density of 
4x105 cells/well onto 6-well plates. Following 24 h of incuba-
tion, 5-AZA (1.5 mM) or TSA (1 µM) was added. Following 
16 h of treatment, the cells were trypsinized (EuroClone 
S.p.A.) and transferred to the upper Matrigel chamber in 500 µl 
medium at a density of 2.5x104. Medium supplemented with 
10% fetal bovine serum (EuroClone S.p.A.) was added to the 
lower chamber. Following 48 h of incubation, the non-migrated 
cells in the upper chamber were carefully removed with a cotton 
tip and the adherent cells present on the lower surface of the 
Matrigel insert were fixed with 100% methanol and stained with 
Giemsa solution (1:10; Sigma-Aldrich Srl). Migrated cells were 
counted microscopically (CK2 microscope; Olympus, Tokyo, 
Japan) in four randomly selected fields of the membrane at a 
magnification of x40. Each invasion experiment was carried out 
in duplicate and repeated at least twice. Data are expressed as 
a percentage of invasion through the Matrigel matrix, relative 
to that of the untreated controls. In parallel, cell growth assays 
were performed under identical conditions.
NF‑κB activation. The DNA-binding capacity of NF-κB (p65 
subunit) was determined in the nuclear extracts of SUM 159 cells 
using the TransAM™ NF‑κB and Nuclear Extract™ kits 
(Active Motif, Carlsbad, CA, USA) according to the manufac-
turer's instructions. The SUM 159 cells were treated with 10 or 
20 µg/ml DHMEQ for 8 or 16 h. Briefly, the determination of 
binding capacity was based on a 96‑well plate, upon which an 
oligonucleotide containing the NF-κB consensus binding site 
Table V. Cell growth inhibition and combination indices in SUM 159 cells following combination treatment with various con-
centrations of 5‑AZA, TSA and DHMEQ.
Treatment Cell growth inhibition, % Combination index
5-AZA (0.5 mM)+TSA (0.5 µM) 20.2±2.4a 0.941
5-AZA (0.5 mM)+TSA (1.0 µM) 34.9±4.1a 1.175
5‑AZA (0.5 mM)+TSA (1.5 µM) 61.9±5.8a 1.105
5-AZA (0.75 mM)+TSA (0.5 µM) 21.3±3.2a 1.089
5‑AZA (0.75 mM)+TSA (1.0 µM) 34.3±2.6a 1.327
5‑AZA (0.75 mM)+TSA (1.5 µM) 69.8±5.3a 1.053
5-AZA (1.0 mM)+TSA (0.5 µM) 17.1±3.0a 1.376
5-AZA (1.0 mM)+TSA (1.0 µM) 47.3±2.3a 1.206
5-AZA (1.0 mM)+TSA (1.5 µM) 80.0±3.7a 0.936
5‑AZA (2.0 mM)+TSA (0.5 µM) 54.8±6.0a 1.129
5-AZA (2.0 mM)+TSA (1.0 µM) 87.2±3.3a 0.810
5-AZA (2.0 mM)+TSA (1.5 µM) 99.3±0.7a 0.342
DHMEQ (7.5 µg/ml)+TSA (0.5 µM) 35.1±2.9a 0.662
DHMEQ (7.5 µg/ml)+TSA (1.5 µM) 64.9±6.7a 0.716
DHMEQ (10 µg/ml)+TSA (0.5 µM) 41.7±6.5a 0.659
DHMEQ (10 µg/ml)+TSA (1.0 µM) 77.2±5.7a 0.608
DHMEQ (15 µg/ml)+TSA (0.5 µM) 72.0±2.7a 0.482
DHMEQ (15 µg/ml)+TSA (1.0 µM) 87.9±2.3a 0.507
DHMEQ (20 µg/ml)+TSA (0.5 µM) 88.5±1.5a 0.366
DHMEQ (20 µg/ml)+TSA (1.0 µM) 84.2±3.1a 0.628
aP<0.01 vs. control. Data are expressed as the mean ± standard deviation of three independent experiments. 5-AZA, 5-aza-2'-deoxycytidine; 
TSA, trichostatin A; DHMEQ, dehydroxymethylepoxyquinomicin.
Figure 1. Effect of treatment with 5-AZA (500 µM, 1 and 2 mM for 72 h) 
on methylation of the Raf-1 kinase inhibitor protein gene promoter in 
SUM 159 cells. The results are representative of two independent experi-
ments with comparable outcomes. 5-AZA, 5-aza-2'-deoxycytidine; U, 
unmethylated; M, methylated.
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(5'‑GGGACTTTCC‑3') was immobilized. Activated NF‑κB 
contained in the extracts is able to specifically bind to this nucle-
otide. NF-κB bound to the oligonucleotide may subsequently be 
detected using an antibody directed against an epitope on p65 
(polyclonal rabbit anti-human; cat. no. 40096; 1:1,000; Active 
Motif), accessible only when NF-κB is bound to its target DNA.
Subsequently, the addition of a horseradish peroxi-
dase-conjugated secondary antibody provided a sensitive 
colorimetric readout that may be quantified by densitometry 
(iMark Microplate Reader; Bio-Rad Laboratories, Inc.). The 
specificity of the assay was confirmed by simultaneous incu-
bations in the presence of excess, non-immobilized consensus 
oligonucleotides, as a competitor, or of a mutated consensus 
oligonucleotide. The results were expressed as arbitrary units: 
one unit indicated the DNA binding capacity exerted by 
2.5 µg whole cell extract from Jurkat cells (positive control 
for NF-κB p65 activation; Active Motif) (stimulated with 
12-O-tetradecanoylphorbol-13-acetate and calcium ionophore) 
per microgram of protein from the nuclear extracts.
Statist ical analysis. Results are presented as the 
mean ± standard deviation. The significance of differences 
between means was evaluated by Student's t-test for unpaired 
samples. The association between miR-224 and RKIP 
mRNA or protein levels (Table I) was evaluated by calcu-
lating Pearson's correlation coefficient (r). P<0.05 indicated a 
statistically significantly difference. 
Results
RKIP expression levels are low in the SUM 159 breast cancer 
cell line. The RKIP content of the non-malignant MCF 10A 
breast epithelial cells and of several breast cancer cell 
lines, including MCF 7 and its multi-drug resistant variant 
MCF 7R, as well as the TNBC MDA MB 231, MDA MB 468, 
BT 549, SUM 149, SUM 159 and MCF 10A cell lines were 
evaluated (Table I). Together with BT 549, the SUM 159 cell 
line was found to express low levels of RKIP, at the mRNA 
and protein level, and therefore this cell line was selected 
for further analysis of the potential mechanisms involved in 
the repression of RKIP. SUM 159 cells are highly invasive, 
originate from a primary anaplastic, grade 4 carcinoma 
and belong to the basal B mesenchymal stem-like subtype 
according to the classification outlined by Neve et al (20).
Demethylating agent 5‑AZA demethylates the RKIP gene 
promoter, increases RKIP expression and inhibits invasion 
Figure 2. NF-κB (p65 subunit) DNA binding capacity in nuclear extracts 
of SUM 159 cells. The cells were treated for 8 or 16 h with DHMEQ 
(10 or 20 µg/ml). Results are expressed as arbitrary units/µg protein of 
SUM 159 nuclear extracts. Results are presented as the mean ± standard 
deviation of a representative experiment carried out in duplicate. *P<0.05, 
**P<0.01 vs. control. NF‑κB, nuclear factor-κB; DHMEQ, dehydroxymethy-
lepoxyquinomicin.
Table VI. Flow cytometric analysis of apoptosis in 
SUM 159 cells following treatment with 5-AZA, TSA, 
DHMEQ or a combination of these.
A, 5-AZA and TSA
Conditions Apoptosis, % Expected, %
Control 3.7±0.1
5-AZA, mM
  2.0 16.9±1.3
  3.0 41.2±2.0
TSA, µM
  1.0 18.3±0.6
  2.0 41.2±1.8
Combinations
  5‑AZA (2.0 mM)+TSA (1.0 µM) 37.2±2.5 31.5±0.6
  5-AZA (2.0 mM)+(TSA 2.0 µM) 79.8±5.4 54.4±3.0a
  5‑AZA (3.0 mM)+TSA (1.0 µM) 64.5±1.6 56.0±2.7
  5-AZA (3.0 mM)+TSA (2.0 µM) 81.3±2.8 78.9±0.3
B, DHMEQ and TSA
Conditions Apoptosis, % Expected, %
Control 3.8±0.1
DHMEQ, µg/ml
  15 15.2±1.1
  20 18.5±0.1
TSA, µM
  1.0 19.8±1.2
  1.5 25.4±0.5
Combinations
DHMEQ (15 µg/ml)+TSA (1.0 µM) 59.4±1.9 31.1±2.4b
DHMEQ (15 µg/ml)+TSA (1.5 µM) 62.2±1.7 36.8±1.8b
DHMEQ (20 µg/ml)+TSA (1.0 µM) 64.3±0.8 34.5±1.2b
DHMEQ (20 µg/ml)+TSA (1.5 µM) 74.6±2.4 40.1±0.5b
aP<0.05 and bP<0.01 vs. observed. Data are expressed as the 
mean ±standard deviation of two independent experiments. Expected 
value: Sum of the effects of the agents alone minus that of the 
untreated cells.  5-AZA, 5-aza-2'-deoxycytidine; TSA, trichostatin A; 
DHMEQ, dehydroxymethylepoxyquinomicin.
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of SUM 159 cells. It has been debated whether epigenetic 
changes, including methylation of the RKIP gene promoter, 
may be responsible for RKIP downregulation in colorectal and 
other types of cancer (11,21-24).
Methylation‑specific PCR was performed on 10 primary 
ductal infiltrating breast cancers of various subtypes and 
with differing grades of RKIP expression (Table II) and in 
SUM 159 cells (Fig. 1). Gene promoters were considered 
methylated if the intensity of methylated bands was >10% of 
their respective unmethylated bands (25). Five of the clinical 
tumors exhibited RKIP gene promoter hypermethylation, 
which was associated with the low expression of RKIP 
protein and mRNA levels. In addition, SUM 159 cells demon-
strated hypermethylation of the RKIP promoter (Fig. 1). 
The SUM 159 cells were subsequently exposed to various 
concentrations (500 µM, 1 and 2 mM) of demethylating agent 
5-AZA for 72 h. The 5-AZA reagent was able to demethylate 
the RKIP gene promoter in a dose-dependent manner (Fig. 1) 
and to increase RKIP expression at the mRNA and protein 
level (Table III). Conversely, in cell invasion assays, 5-AZA, 
at a concentration of 1.5 mM, which was only marginally 
cytotoxic (3.7±0.2% inhibition of cell growth), markedly 
inhibited (82.5±2.1%) the invasion of SUM 159 cells.
HDAC inhibitor TSA enhances RKIP expression and inhibits 
invasion in SUM 159 cells. It is well known that another 
epigenetic mechanism that affects gene expression is histone 
acetylation (26). Notably, the HDAC inhibitor TSA was 
able to increase the mRNA and protein expression levels of 
RKIP (Table III) in SUM 159 cells, as well as exert inhibi-
tory effects in the specific assays determining their invasion 
ability (45.9±3.1% at 1 µM, which induced 12.2±1.6% cell 
growth inhibition).
The combination of 5-AZA and TSA analyzed was not 
able to further increase the effects of either agent on RKIP 
mRNA and protein expression levels (Table III). The effects 
of 5-AZA and TSA alone or in combination on the inhibition 
of cell growth were evaluated using MTS assays (Tables IV 
and V). 5-AZA and TSA treatment both inhibited cell growth 
in a dose dependent manner (Table IV). The combinatory 
effects were found to be substantially additive, as indicated 
by the combination indices (Table V). Furthermore, flow 
cytometric analysis of the induction of apoptosis revealed 
that, overall, the combination of 5‑AZA+TSA produced only 
modest increases in apoptosis with respect to the expected 
sum, based on the effects of the agents alone (Table VIA).
DHMEQ reduces constitutive activation of NF‑κB and 
increases RKIP levels in SUM 159 cells. Previous studies 
have indicated that activated NF‑κB is able to downregulate 
RKIP expression via Snail induction (13,14,27). Evaluation 
by TransAM® assays revealed that SUM 159 cells exhib-
ited a marked constitutive activation of NF‑κB, which was 
reduced in a concentration‑dependent manner by DHMEQ, 
an inhibitor of the nuclear translocation of this transcription 
factor (Fig. 2) (28,29). Furthermore, identical treatments with 
DHMEQ induced marked increases in RKIP mRNA and 
protein expression in SUM 159 cells (Table VII).
Notably, combined treatment with DHMEQ and TSA 
produced synergistic effects on the inhibition of cell growth 
(Table V) and induction of apoptosis (Table VIB).
miR‑224 does not alter RKIP expression levels. Upregulation 
of miRNAs has previously been associated with cancer 
progression, via the inhibition of tumor suppressor 
genes (30,31). Furthermore, a previous study (16) demon-
strated that miR-224 was able to inhibit RKIP gene expression 
by directly targeting the 3'-untranslated region of the highly 
invasive MDA MB 231 breast cancer cell line.
However, by calculating the Pearson's correlation coef-
ficient, a significant inverse association between miR‑224 and 
Figure 3. Reverse transcription‑quantitative polymerase chain reaction anal-
ysis of miR-224 expression in the SUM 159 cell line following no treatment 
(Control), treatment with siPORT Amine Transfection Agent, anti-miR-224 
miRNA inhibitor (30 nM), pre-miR-224 miRNA precursor (30 nM) or its 
negative control (30 nM) for 24 h. Relative quantification (2-ΔΔCT) values 
normalized against RNU6B small RNA are shown on the y axis on a linear 
scale. The data shown are the mean ± standard error of the mean of a repre-
sentative experiment carried out in duplicate. *P<0.05, **P<0.01 vs. control. 
miR-224, microRNA-224; miRNA, microRNA.
Table VII. RKIP mRNA and protein levels of SUM 159 cells 
following treatment with DHMEQ for 8 or 16 h.
Conditions Duration, h RKIP mRNA RKIP protein
Control 0 1.000 0.654
DHMEQ, µg/ml
  10 8 1.218 0.983
  20 8 1.302 0.870
  10 16 1.375 1.780
  20 16 1.285 1.537
Untreated SUM 159 cells were used as control reference for the deter-
mination of RKIP mRNA expression levels by quantitative polymerase 
chain reaction. For RKIP protein expression analysis, immunoblots 
were quantified by densitometry and results are expressed as arbitrary 
units (RKIP/β-actin). The data shown are the results of a representa-
tive experiment. A repeat experiments produced very similar results. 
RKIP, Ras‑1 kinase inhibitor protein; DHMEQ, dehydroxymethy-
lepoxyquinomicin; mRNA, messenger RNA.
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RKIP levels could not be found in the breast cancer cell lines 
evaluated in the present study (Table I).
Furthermore, SUM 159 cells were transfected with 
pre-miR-224 miRNA precursor, anti-miR-224 miRNA inhibitor 
or siPORT Amine Transfection Agent alone or with a negative 
control for 24 h. The increase or reduction in miR-224 (Fig. 3) 
induced by the precursor or inhibitor, respectively, did not alter 
RKIP expression at the mRNA or protein level (data not shown).
Discussion
Overall, the present results suggest that various mechanisms, 
including methylation of the gene promoter, histone deacety-
lation and NF-κB activation, but not targeting by miR‑224, 
may be responsible for the downregulation of RKIP gene 
expression in the highly invasive SUM 159 TNBC cell line. 
However, previous studies of hepatocellular carcinoma cell 
lines (11,32) ruled out the role of gene methylation, histone 
acetylation and miR-224 in the reduction of RKIP expression. 
These results highlight the complexity of the regulation of this 
tumor suppressor gene, which may be differentially affected 
depending on the type of cancer. From a therapeutic perspec-
tive, the demethylating agent 5‑AZA, the HDAC inhibitor TSA 
and the NF-κB inhibitor DHMEQ, in addition to inducing an 
increase in RKIP expression, appeared to be able to generate 
significant cytotoxicity, induce apoptosis and, in the case of 
5-AZA and TSA, reduce cell invasion. Results in other cell 
models have demonstrated that the combination of DNA 
demethylating agents and HDAC inhibitors, for example 
5‑AZA and TSA, may be synergistic in the reactivation of 
specific genes (33,34). However, this did not appear to be the 
case for RKIP in SUM 159 cells. Furthermore, 5-AZA and 
TSA generated mainly additive effects on cell growth inhibi-
tion and induction of apoptosis when the cells were treated 
with the two agents together. The combination of DHMEQ 
and TSA exhibited significant synergy in cell growth and 
induction of apoptosis assays. This was unsurprising, since, 
besides influencing RKIP expression, 5-AZA, TSA and 
DHMEQ may distinctly influence additional genes, and there-
fore their respective properties may determine their respective 
capabilities of synergizing with other agents, with regard to the 
inhibition of cell growth, survival and invasive and metastatic 
ability. Concurrently, it was previously demonstrated that TSA 
and DHMEQ were able to diversely alter gene expression 
and synergize with conventional chemotherapeutic drugs, 
including doxorubicin and cisplatin, in hepatocellular cancer 
cells (29,32).
The present results, in addition to confirming the potential 
significance of NF‑κB activation in the downregulation of RKIP 
expression (13,14,27), suggest that this transcription factor may 
be a useful target for the treatment and chemosensitization of 
the most aggressive forms of breast cancer. There is increasing 
evidence that aberrant activation of NF-κB signaling is a 
frequent characteristic of TNBC cells, although the underlying 
causes of this activation have remained largely elusive (35,36). 
Apart from DHMEQ, which at preclinical levels appears to 
be a promising agent for anticancer, anti‑inflammatory and 
immunosuppressive treatments (28), other valuable thera-
peutic resources in this context may include the proteasome 
inhibitors, which, in addition to inhibiting NF-κB activation, 
may also restore RKIP levels via inhibition of proteasome 
degradation of the ubiquinated protein (11,37).
In conclusion, the present findings, in addition to other 
potential causes of RKIP downregulation, require further inves-
tigation and validation in a larger number of TNBC cell models.
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